ClinicalTrials.gg
CompletedNCT04197661Updated Dec 17, 2020

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects

A Phase 1 interventional study of HSK3486 and HSK3486 in Healthy Elderly Subjects, sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-17.

Sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

It is a single-center, open-label, dose-finding, Phase I clinical study evaluating the pharmacokinetics, pharmacodynamics, and safety characteristics of HSK3486 in healthy elderly subjects.

02

Conditions studied

  • Healthy Elderly Subjects

Keywords

  • Healthy Elderly Subjects
03

In context

Lead sponsor

Sichuan Haisco Pharmaceutical Group Co., Ltd is the lead sponsor of 30 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the form and fully understand the content, procedure and possible adverse effects before the trial starts;
  2. Able to complete the study in compliance with the requirements of the clinical trial protocol;
  3. Subjects (including their partners) are willing to voluntarily adopt an effective measure of starting from screening to 6 months after the last dose of the drug. See the attachment for specific contraceptive measures;
  4. Males and females with full capacity for civil conduct, aged ≥ 18 years old (aged between 18 and 64 years old for the non-elderly group and ≥ 65 years old for the elderly group (inclusive));
  5. Females weighing ≥ 45 kg and males weighing ≥ 50 kg, and with a (BMI) of ≥ 18 and ≤ 30 kg/m2 (BMI = Weight (kg)/height2(m2))(inclusive);
  6. For all subjects, the body temperature should be between 35.9-37.6 °C, respiratory rate between 12-20 breaths/min, and SpO2 when inhaling > 95%; in addition, for subjects in the non-elderly group, the blood pressure should be between 90-140/60-90 mmHg and heart rate between 60-99 bpm; for those in the elderly group, the blood pressure should be between 90-160/60-100 mmHg and heart rate between 50-100 bpm;

Exclusion criteria

Exclusion Criteria:

  1. Smoke more than 5 cigarettes per day on average within 3 months prior to screening;
  2. Patient having to deep sedation/general anesthesia or a history of past sedation/anesthesia accidents;
  3. Known sensitivity to HSK3486 (soybean oil, glycerin, triglyceride, egg lecithin, sodium oleate, and sodium hydroxide); or history of drug allergies (including other anesthetics), allergic diseases, or those with hyperactive immuneresponse(allergies to various drugs and foods);
  4. History of drug abuse or any signs of long-term use of benzodiazepines (such as insomnia, anxiety, spasms) within 3 months prior to screening;
  5. Acute diseases with clinical significance (determined by the investigator) within 2 weeks prior to screening, including GI diseases and infections (such as respiratory or CNS infections);
  6. History or evidence of cardiovascular diseases prior to screening: Uncontrolled hypertension [SBP ≥ 170 mmHg and/or DBP ≥ 105 mmHg without antihypertensive treatment, or SBP > 160 mmHg and/or DBP > 100 mmHg despite antihypertensive treatment], postural hypotension, severe arrhythmia, heart failure, Adams-Stokes syndrome, unstable angina, myocardial infarction within 6 months before screening, history of tachycardia/bradycardia requiring medication, II-III degree atrioventricular block (excluding patients with pacemakers), or interval ≥ 450 ms (Fridericia's correction formula);
  7. Subjects judged by the investigator to be unsuitable for participating in this trial for any reason.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    Elderly groupⅠ

    Elderly groupⅠ 65 years or older 0.2 mg/kg HSK3486

    Drug: HSK3486

  • Active comparator
    Elderly group Ⅱ

    Elderly group Ⅱ 65 years or older 0.3 mg/kg HSK3486

    Drug: HSK3486

  • Active comparator
    Elderly group Ⅲ

    Elderly group Ⅲ 65 years or older 0.4 mg/kg HSK3486

    Drug: HSK3486

  • Active comparator
    Non-elderly group IV

    Non-elderly group IV 18 to 64 years 0.4 mg/kg HSK3486

    Drug: HSK3486

Interventions

  • Intravenously infuse 0.2 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.

    Also known as: HSK3486 0.2 mg/kg

  • Intravenously infuse 0.3 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.

    Also known as: HSK3486 0.3 mg/kg

  • Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.

    Also known as: HSK3486 0.4 mg/kg

  • Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.

    Also known as: HSK3486 0.4 mg/kg

06

What researchers measure

Primary outcomes

  1. Peak concentration (Cmax)

    Cmax(a measure of the body's exposure to HSK3486)will be compared between non-elderly subjects and elderly subjects.

    Time frame: -30 minutes before administration until 24 hours post administration on day 1

  2. Area under the concentration-time curve(AUC)

    AUC(a measure of the body's exposure to HSK3486)will be compared between non-elderly subjects and elderly subjects.

    Time frame: -30 minutes before administration until 24 hours post administration on day 1

Secondary outcomes

  1. MOAA/S(modified observer's assessment of alert /sedation)

    modified observer's assessment of alert /sedation

    Time frame: -5 minutes before administration until 1 hours post administration on day 1

  2. Bispectral index(BIS)

    Bispectral index

    Time frame: -5 minutes before administration until 1 hours post administration on day 1

  3. Tmax

    time to peak observed

    Time frame: -30 minutes before administration until 24 hours post administration on day 1

  4. Total clearance

    Total clearance

    Time frame: -30 minutes before administration until 24 hours post administration on day 1

  5. blood pressure(systolic, diastolic and mean arterial pressure)

    safety endpoits

    Time frame: from the screening to 2 days post-dose

07

Study locations

1 site
  • Phase I Clinical Trial Laboratory, The First Hospital of Jilin University
    Chang chun, Ji Lin 130021, China
08

References and documents

Publications

  • Qin L, Ren L, Wan S, Liu G, Luo X, Liu Z, Li F, Yu Y, Liu J, Wei Y. Design, Synthesis, and Evaluation of Novel 2,6-Disubstituted Phenol Derivatives as General Anesthetics. J Med Chem. 2017 May 11;60(9):3606-3617. doi: 10.1021/acs.jmedchem.7b00254. Epub 2017 Apr 28. PubMed 28430430 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Jan 2020, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2019
First posted
Dec 13, 2019
StartActual
Dec 25, 2019
Primary completionActual
Jan 22, 2020
CompletionActual
May 22, 2020
Last update
Dec 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04197661
Responsible party
Sponsor
First posted
Dec 13, 2019
Start date
Dec 25, 2019
Primary completion
Jan 22, 2020
Completion
May 22, 2020
Last update
Dec 17, 2020

Study contacts

Yanhua Ding, PhD
study director · Phase I Clinical Trial Laboratory,The First Hospital of Jilin University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciprofol

Start the discussion